Nitroimidazole Nitrofuran Metabolic rate Mutagen specific activity DT-Diaphorase (NQO1) NQO2 Delamanid a b s t r a c t Nitro-containing compounds such as nitrofuran and nitroimidazole are drugs used for the treatment of infectious diseases. However, many of these nitro-containing drugs are positive in the bacterial reverse mutation assay (Ames test). The recently approved anti-multidrug-resistant tuberculosis (MDR-TB) drug, delamanid (Deltyba™; OPC-67683), a derivative of 4-nitroimidazole, was negative for mutagenicity in the Ames assay. In Salmonella typhimurium, mutagenicity of nitro compounds has been closely associated with the ability of nitroreductase to metabolize (degradation)these compounds. To explore the lack of mutagenicity for delamanid, we examined the initial metabolic rate and mutagenic-specific activity of a series of nitro compounds in S. typhimurium TA100. The order of maximum mutagenic-activity was nitrofuran > 2-nitroimidazole > 5-nitroimidazole ! 4-nitroimidazole, which is very similar to the order of initial metabolic rate, i.e., the Pearson's correlation coefficient (r ¼ 0.85) showed a correlation between metabolic rate and mutagenic-activity. No metabolism of delamanid was detected even after 60 h of treatment. In addition, delamanid was not reduced by two human nitroreductases. These facts may explain the absence of genotoxicity of delamanid in both in vitro and in vivo tests.
Introduction
Nitro-containing compounds nitrofuran and nitroimidazole are used for the treatment of a wide variety of infectious diseases. They are not only used as an anti-bacterial [e.g., Furazolidone (FZD; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one)], but also as anti-protozoal [e.g., nifurtimox ((R,E)-3-methyl-4-{[(5-nitrofuran-2-yl)methylene]amino}thiomorpholine 1,1-dioxide)] agents. Furthermore, some nitroimidazoles have activity against fungi {satranidazole; [1-(1-methyl-5-nitroimidazol-2-yl)-3-methylsulfonylimidazolidin-2-one]} and HIV {DAMNIs; 1-[2(Diarylmethoxy) ethyl]-2-methyl-5-nitroimidazoles} (Mital, 2009) .
While nitrofuran and nitroimidazole drugs are therapeutically active, risk of mutagenicity is a concern for the development of these compounds. Many of these drugs are positive in the bacterial reverse mutation assay (Ames test). Nitrofuran drugs such as furazolidone (FZD), and nitrofurantoin (NIT) are Ames positive agents and are banned for use in food-producing animals in the US (USFDA, 2014) . Not all nitroimidazoles are mutagenic. Delamanid (DLM) (Deltyba™; OPC-67683), a recently approved antimultidrug-resistant tuberculosis (MDR-TB) drug is a derivative of 4-nitroimidazole was not mutagenic in the Ames assay (Matsumoto et al., 2006) . Furthermore, DLM was not genotoxic in a series of in vitro and in vivo studies. The in vitro genotoxicity tests include a bacterial reverse mutation assay (AMES test) and mouse lymphoma L5178/tk assay. The in vivo test is rat bone marrow micronucleus test. And in mice and rats, repeated oral administration of delamanid for up to 104 weeks did not appear to be carcinogenic (CHMP, 2013) . Therefore, the mutagenicity of nitro compounds exhibit Abbreviations: Multidrug-resistant tuberculosis, (MDR-TB); Furazolidone, (FZD); Nitrofurantoin, (NIT); Metronidazole, (MTZ); Benznidazole, (BZN); 2-nitroimidazole, (2NIT); 4-nitroimidazole, (4NIT); 1-(2-Aminoethyl)-2-methyl-5-nitroimidazole dihydrochloride, (12A); N-Benzyl oxymethyl-4-nitroimidazole, (NBenz); Delamanid, (DLM); CGI-17341, (CGI); OPC-37464, (464); 2-(2-Furyl)-3-(5-nitro-2-furyl) acrylamide, (AF-2); Phosphate buffered saline, (PBS); Internal standard, (IS); High-performance liquid chromatography, (HPLC); Dimethyl sulfoxide, (DMSO); Trifluoroacetic acid, (TFA).different mutagenic potential. One key determinant of mutagenicity of nitro compounds may be the ability of nitroreductases to act on the nitro group in these compounds. Nitroreductase is capable of catalyzing the reduction of nitrosubstituted compounds using reducing co-factors (Oliveira et al., 2010) . In Salmonella typhimurium, mutagenicity of nitro compounds was closely associated with nitroreductases SnrA and Cnr (Salamanca-Pinz on et al., 2006; Watanabe et al., 1989; Yamada et al., 1997) . The Cnr nitroreductase knockout strain of S. typhimurium showed lower sensitivity whereas Cnr high-expression strain of S. typhimurium showed higher sensitivity to nitro mutagenic compounds than TA100 (Watanabe et al., 1989; Yamada et al., 1997) . SnrA is also a nitroreductase which is mainly responsible for the reduction of nitrofurans in S. typhimurium (Salamanca-Pinz on et al., 2006). The present study examined the initial metabolic rate by S. typhimurium and mutagen specific activity of four groups of nitro aromatic skeletons; two nitrofurans, two 2-nitroimidazoles, two 5-nitroimidazoles, and five 4-nitroimidazoles. We then examined whether DLM can be degraded by human nitroreductases. Our findings suggest that the metabolism of nitro compounds by S. typhimurium strongly correlates with mutagenic activity. The fact that DLM is not degraded by human nitroreductases may explain why it has no genotoxicity in both in vitro and in vivo testing.
Materials and methods

Compounds and enzymes
The nitro compounds we used in this study are listed in Table 1 . FZD, NIT, metronidazole (MTZ), and benznidazole (BZN) were purchased from Sigma Aldrich (St Louis, MO, USA). 2-Nitroimidazole (2NIT), 4(5)-Nitroimidazole (4NIT), and 2-(2-Furyl)-3-(5-nitro-2-furyl) acrylamide (AF-2) were purchased from Wako Pure Chemical (Osaka, Japan). 1-(2Aminoethyl)-2-methyl-5-nitroimidazole dihydrochloride (12A) was purchased from Kanto Chemical (Kanto Chemical, Tokyo, Japan). N-Benzyl oxymethyl-4-nitroimidazole (NBenz) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). DLM, CGI-17341 (CGI), and OPC-37464 (464) were synthesized at Otsuka Pharmaceutical (Tokyo, Japan). Since 4-nitroimidazole and 5-nitroimidazole are tautomer, it could not be categorized in 4-nitroimidazole nor 5-nitroimidazole group. We made one group 4(5)-nitroimidazole for this molecule. Two human nitroreductases NQO1 and NQO2 (recombinant, expressed in Escherichia coli) were also purchased from Sigma Aldrich. The activities of NQO1 and NQO2 were 558 and 617 units/mg, respectively.
Ames assay
The Ames test was performed based on the description with the Organisation for Economic Co-operation and Development Test Guideline plate incorporation method (OECD, 1997) . S. typhimurium TA100 from frozen stock were pre-cultured in OXOID Nutrient Broth No.2 (Thermo Scientific, Waltham, MA, USA) for 8 h at 37 C. The culture was measured OD600 and confirmed the OD600 value was more than 2.5. The culture was centrifuged and the pellet was resuspended with the same amount of phosphate buffered saline (PBS). Test compounds were adjusted to 5 mg/mL with dimethyl sulfoxide (DMSO) and were diluted 4-fold with DMSO. The final doses used in the assay were 0.00119e5000 mg/plate. For positive control, 0.1 mg/mL (0.01 mg/plate) AF-2{2-(2-Furyl)-3-(5-nitro-2-furyl) acrylamide} was used and for negative control, DMSO was used (USFDA, 2000) . A 2.0 mL volume of top agar (Bacto agar: 8.0 g/ L, NaCl: 5.0 g/L, biotin: 0.05 mmol/L L-histidine: 0.05 mmol/L) was mixed with a 0.1 mL volume of each test and reference compound and then spread onto Tesmedia ® AN (Oriental Yeast, Tokyo, Japan).
Each test plate was duplicated. The plates were inverted and incubated at 37 C for 48 h. Thenumbers of revertants on the plates were counted. Only plates without precipitation were used in this study. The result was classified as Ames positive only if the plate had twice the number of colonies of the negative control plate. In addition, to quantitatively compare the mutagenic activity, the mutagen specific activity of each Ames positive concentration was calculated. The calculation was conformed to the Japanese Industrial Safety and Health Act, Article 57 (MHLW, 1972) . The values were calculated as dividing number of increased colonies by the amount of the test compound. Then, the highest value was selected (maximum mutagen specific activity). Mutagen specific activity:
2.3. Metabolism of nitro compounds by S. typhimurium S. typhimurium TA100 from frozen stock were pre-cultured in Oxoid nutrient broth No.2 (Thermo Scientific) for 16 h. The culture was centrifuged and the pellet was re-suspended with the same amount of PBS. The nitro compounds were dissolved in DMSO to prepare 1.0 mM stock solutions, which were then diluted at a 1:100 ratio with the bacterial culture or PBS (negative control). The mixtures were incubated in an incubator set at 37 C for 1e3600 min, and then the compounds were extracted with twice the volume of an acetonitrile solution containing the internal standard (IS). The samples were centrifuged and the supernatants were stored at À15 C or lower until measurement. The concentration of nitro compounds in the samples was measured by highperformance liquid chromatography (HPLC) analysis.
Reduction assay with human nitroreductases
The 3 mM DLM and FZD in PBS were each mixed with NQO1 or NQO2 in the presence of 0.5 mM bNADH and were incubated at 37 C for 2e24 h. The samples were added to twice the amount of an acetonitrile solution containing an IS. To assess the spontaneous degradation of DLM and FZD in PBS, samples without NQO1 and NQO2 were also examined.
HPLC analysis
HPLC analysis was carried out with the SCL-10A VP HPLC system Average colonies on the test plate À Average colonies on the negative control plate Amount of the test compound nmol plate Table 1 Nitro compounds used in this study.
Skeleton
Compound name 
Statistical analysis
Pearson's correlation coefficient was calculated with the initial metabolic rate and the maximum mutagen specific activity of each compound. To detect significant difference between the nitroreductases treated and untreated samples, linear regression analysis was performed (significant level ¼ 0.05). Data analysis was performed using the SAS software (R9.3; SAS Institute, Tokyo, Japan).
Calculation of initial metabolic rate
The initial metabolic rate was shown as the slope of a tangent at time 0. To calculate the tangent at time 0, the regression formula
À2 . The value of x was 0.
Results
Ames assay
The Ames test was performed with all nitro compounds except DLM (OECD, 1997). DLM is reported as an Ames negative (Matsumoto et al., 2006) . All of the compounds in the groups of nitrofuran, 2-nitroimidazole and 5-nitroimidazole skeleton except 2Nit was Ames positive. On the other hand, two (464 and DLM) out of four 4-nitroimidazoles and 4(5)-nitroimidazole had Ames negative results. To quantitatively compare the mutagenic activity, we calculated mutagen specific activity. The values were calculated as dividing the number of increased colonies by the amount of the test compound. Therefore, the ability of generation of revertants per 1 nmol can be shown as the value. Then, we selected the highest value to evaluate the maximum ability to cause mutagenicity (maximum mutagen specific activity; Table 2 ). This value can be used for comparing the compounds. The nitrofuran group had the highest maximum mutagen specific activities among all nitro compounds, with furazolidone and nitrofurantoin showing over 5000 colonies/nmol maximum mutagen specific activities. The next groups were the 5-nitroimidazoles and 2-nitroimidazoles with more than 15 colonies/nmol maximum mutagen specific activities with the exception of 2Nit and 12A, which had low activity. The 4-nitroimidazole and 4(5)-nitroimidazole groups had the lowest maximum mutagen specific activities with three Ames negative compounds (4Nit, 464, and DLM) and the remaining two (CGI and NBenz) showing maximum mutagen specific activities of less than 15 colonies/nmol.
Metabolism assay with S. typhimurium TA100
To determine the initial metabolic rate, 10 mM of the nitro compounds were mixed with S. typhimurium and the concentration of the remaining compound (not metabolized) was analyzed by HPLC (Fig. 1) .
In the initial phase of the reaction, the metabolized amount and times were proportional but in the late phase, metabolized amount reached the plateau. This trend fits well with the Emax model. Therefore, to determine the initial metabolic rate of the nitro compounds, regression formulas using the metabolized amount and time were calculated using an Emax model (SAS software R9.3; SAS institute, Tokyo, Japan). In this formula, the initial metabolic rates were indicated as the slope of a tangent at time 0. The values of the initial metabolic rate are shown in Table 2 . Nitrofurans had the highest initial metabolic rates among the four groups with more than 1.8 mM/min. The next group was 2-nitroimidazole with more than 0.04 mM/min. The groups of 5-nitroimidazole, 4(5)-nitroimidazole, and 4-nitroimidazole showed the lowest initial metabolic rate with 0.0045e0.0361 mM/min and less than 0.009 mM/min, respectively. DLM was not metabolized even after 3600 min, as the total un-metabolized DLM with S. typhimurium at the longest time point (3600 min) was similar to those from the control (PBS; Fig. 2 ). The order of initial metabolic rate was nitrofuran > 2-nitroimidazole > 5-nitroimidazole ! 4(5)-nitroimidazole 2 4-nitroimidazole. This order is consistent with the order of maximum mutagen specific activity, with a Pearson's correlation coefficient of 0.85 between the metabolic rate and the mutagen specific activity (Fig. 3) .
Reduction assay with human nitroreductases
Because previous studies have shown that mutagenicity of nitro compounds is closely associated with nitroreductases Cnr and SnrA in S. typhimurium, we postulated that reduction of nitro compounds by human nitroreductases may be able to predict mutagenicity in a human cell (Salamanca-Pinz on et al., 2006; Watanabe et al., 1989; Yamada et al., 1997) . FZD was used as a positive control, since it is known to cause DNA damage in the human hepatic cell line HepG2, and such damage can be reduced by the inhibition of human NQO1 (DT diaphorase; Hasspieler et al., 1997; Jin et al., 2011) .
FZD was reduced concentration-dependently by both human nitroreductases NQO1 and NQO2 at concentrations of 10 mg/mL and higher (Fig. 4) .
More than 50% of the 3 mM FZD was reduced within 24 h of incubation with 10 mg/mL NQO1 and 80% with 100 mg/mL NQO1 in 2 h (Fig. 4A) . Reduction of FZD by NQO2 followed the same trend.
With NQO2 at 10 mg/mL and higher, 3 mM FZD was almost entirely reduced within 24 h (Fig. 4B) . However, DLM concentration was stable as it did not show any significant reduction when incubated with NQO1 and NQO2 (Fig. 5) . The concentrations of DLM in NQO1 and NQO2 incubated samples overlapped with those incubated with PBS.
Discussion
While nitrofuran and some nitroimidazole drugs are positive on Ames test, DLM is Ames test negative (Matsumoto et al., 2006) . DLM showed no genotoxicity in a series of in vitro and in vivo tests (CHMP, 2013 ). In the current study, we showed that the mutagenicity of nitro compounds is highly correlated with metabolic rate of the compound by nitroreductase, although some discrepancies were observed: 2NIT, 464 and 4NIT were metabolized at low rates but demonstrated no mutagenic activities. One possible explanation is the use of whole S. typhimurium cells in this study, which may contain enzymes other than nitroreductases that can also metabolize the compound.
In this study, we performed Ames tests based on the instructions in the OECD Test Guideline, but with several modifications (OECD, 1997) including the 1) S9 mix used, the 2) interval for test concentrations, and the 3) strain used. In detail, 1) we did not use the S9 mix because the S9 mix is used to mimic animal metabolism in Salmonella and is thus used to detect mutagenicity in metabolized test compounds of Salmonella. In this study, the objective was to investigate the correlation between metabolism and mutagenicity in Salmonella itself and, to accomplish this objective, we decided not to use the S9 mix in this study. In addition, 2) we used four-fold intervals as the test concentrations because, for the compounds used in this study, mutagen-specific activity does not differ markedly for Ames positive plates. The compound with the largest difference in mutagen-specific activity between the Ames positive plates was MTZ. There were 17.7 Fig. 4 . FZD is reduced by human nitroreductases NQO1/NQO2. Human nitroreductases NQO1 (A) and NQO2 (B) were mixed with FZD (3 mM) and incubated at 37 C for 2e24 h.
The concentrations of remaining FZD (not reduced) were determined during the treatment at various time points. Mean ± SD, n ¼ 3. Linear regression analysis (linearity, p < 0.01).
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colonies/nmol in the 1250 mg/plate for this compound, 15.0 colonies/nmol (approximately 85% of the value obtained with the 1250 mg/plate) in the 313 mg/plate and 12.0 colonies/nmol (approximately 68% of the value obtained with the 1250 mg/plate) in the 78.1 mg/plate. For this reason, we hypothesized that a fourfold interval would be sufficient to calculate the maximum mutagen specific activity. Last, 3) we only used S. typhimurium TA100 for the Ames assay, because TA1538 (TA98 without pKM101 plasmid) does not have the complete DNA sequence for snrA, one of the nitroreductases (Nokhbeh et al., 2002) . Thus, TA100 is more sensitive to nitrofuran and nitroimidazole than TA98 (Buschini et al., 2009) . There are several known nitroreductase knockout strains but these strains only have mutations in the major nitroreductases Cnr and SnrA. No known knockout strains have shown the absence of all nitroreductase genes. Salmonella typhimurium strain LT2, the principal strain for cellular and molecular biology in Salmonella, has at least three nitroreductases (STM0578 (cnr), STM0874 (snrA), and STM1296). Yamada et al. (1997) found that YG7131 (Cnr knockout strain of TA1538, thus it is Cnr-SnrA double knockout strain) had decreased metabolic activity. There have been numerous papers written about the SnrA/Cnr knockout strains and the corresponding mutagenicity and the strains are known to show decreased sensitivity to nitro compounds (Yamada et al., 1997; Watanabe et al., 1989) . The correlation between metabolic activity and mutagenicity is the same as with the nitroreductase-intact strains. Because only limited knowledge about the nitro compound-nitroreductase specificity is available, we used TA100 that has all the nitroreductases.
The order of mutagenic activities for the groups is nitrofurans > 2-nitroimidazoles > 5-nitroimidazoles ! 4-nitroimidazoles ! 4(5)-nitroimidazoles. Although two 5-nitroimidazole compounds (i.e. 12A and MTZ) are between two 4-nitroimidazole compounds (CGI and NBenz), two (464 and DLM) out of the four 4-nitroimidazole compounds are Ames negative and all of the 5-nitroimidazole compounds are Ames positive. The result for 4(5)-nitroimidazole was Ames negative. This suggests that the order of mutagenic activity is 5-nitroimidazoles ! 4-nitroimidazoles !4(5)-nitroimidazole. On the other hand, the order of initial metabolic rate is nitrofurans > 2-nitroimidazoles > 5-nitroimidazoles ! 4(5)-nitroimidazoles ! 4-nitroimidazoles. We decided the order based on average initial metabolic rate in the logarithmic scale. We did not see clear differences between 5-nitroimidazoles, 4(5)-nitroimidazole and 4-nitroimidazoles. At a very low rate of reaction, the initial metabolic rates are considered to have large variation because the compounds may be modified by non-metabolic reactions. For example, 2-nitroimidazoles are more likely to be modified by substitution than 4-nitroimidazoles (Anderson et al., 2008) . Therefore, the results suggest that the order of mutagenic activities and initial metabolic rates is nitrofurans > 2-nitroimidazoles > 5-nitroimidazoles ! 4(5)-nitroimidazoles 2 4-nitroimidazoles. Rozenski et al. reported that the half wave potentials of FZD, NIT, BZN, 2Nit, MTZ and 4Nit were À237, À251, À331, À473, À514, and À675 mV, respectively (Rozenski et al., 1995) . The half wave potential is consistent with the maximum mutagen specific activities and initial metabolic rates. Rozenski et al. (1995) also reported that the half wave potentials of 74 nitro compounds and general order of electron affinities of nitro groups were 5-nitrofuran > 2-nitroimidazole > 5- nitroimidazole > 4-nitroimidazole. Therefore, the higher the electron affinity of the nitro groups, the higher the mutagenicity. Thus, our data suggest that the difference of the electron affinity may be a key factor to determine the stability of the nitro compounds to the nitroreductases.
It has been shown that DLM can be metabolized by TB bacilli, and the anti-TB activity of DLM and other nitroimidazoles is dependent on a deazaflavin-dependent nitroreductase (ddn; Rv3547)-mediated reduction (Matsumoto et al., 2006; Nokhbeh et al., 2002) . In this study we showed that DLM was not metabolized by S. typhimurium or human nitroreductases. This difference can be explained by the redox potentials of the coenzymes used by the nitroreduction. Mycobacterium uses a unique deazaflavin coenzyme F 420 which has a notably low redox potential of À380 mV. On the other hand, both human and S. typhimurium nitroreductases use NAD(P)H as the electron donor: the nitroreductases of S. typhimurium, SnrA and Cnr, and the human nitroreductases NQO1 and NQO2 catalyze the two-electron reduction of nitrogenoxides with NAD(P)H (Jaiswal, 2000; Nokhbeh et al., 2002; Salamanca-Pinz on et al., 2010) . In addition to NAD(P)H, NQO2 also uses dihydronicotinamide riboside (NRH; Wu et al., 1997) . Though NRH shows superior K M and K cat values than NAD(P)H, we used NADH as a reducing agent to donate electrons because NADH is more widely studied. The redox potential of NADH and NADPH are À320 mV and À324 mV, respectively, much higher than the redox potential of F420. Thus, it appears that only organisms with coenzymes of lower electric potential such as F420 can reduce DLM. Organisms using NAD(P)H nitroreductases such as human and S. typhimurium are not able to reduce DLM. Our data suggest that this may be a reason why DLM demonstrated a negative Ames test and has no mutagenicity.
In conclusion, we demonstrated that mutagenicity of nitro compounds is correlated with the metabolism (nitroreduction) of these compounds by S. typhimurium and human nitroreductase. The higher the metabolism (reduction), the higher the mutagenicity potential. DLM is not metabolized by S. typhimurium nor the human nitroreductases, possibly explaining why it has no mutagenicity. Finally, the ability to resist reduction by human nitroreductases may be used as a criterion to select nitro compounds with no-mutagenicity potential during the drug development process.
